Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Blood Advances|September 3, 2021
Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 studyChristian Buske, Wojciech Jurczak, Juan-Manuel Sancho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2024
Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON)Joshua Tobias, Marina Maglakelidze, Zoran Andrić, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 30, 2023
Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION StudyMyung-Ju Ahn, Igor Bondarenko, Ewa Kalinka, et al.
Lung Cancer (Amsterdam, Netherlands)|February 11, 2026
Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysisCaicun Zhou, Ke-Jing Tang, Baogang Liu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 20, 2019
A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin Alfa for Chemotherapy-Induced Anemia in Patients With Advanced NSCLCPere Gascón, Rajnish Nagarkar, Martin Šmakal, et al.
Cancer Chemotherapy and Pharmacology|April 24, 2023
Rituximab biosimilar for the treatment of diffuse large B-cell lymphoma: a phase 3 randomized study in IndiaAnkit Patel, Niraj Bhatt, S S Prakash, et al.
Clinical Breast Cancer|July 28, 2024
A Randomized, Double-Blind, Phase III Study in India for Comparing Efficacy, Safety, and PK of ZRC-3277 (Pertuzumab Biosimilar) With Perjeta® in Patients With HER2-Positive Metastatic Breast CancerRushabh Kothari, Maulik Doshi, P K Chaithanya, et al.
Pageof 3